Personalis Research and Development Expenses 2018-2026 | PSNL
Personalis research and development expenses from 2018 to 2026. Research and development expenses can be defined as an expense arising from studies and product development processes.
|
Personalis Annual Research and Development Expenses (Millions of US $) |
|
|---|---|
| 2025 | $50 |
| 2024 | $49 |
| 2023 | $65 |
| 2022 | $65 |
| 2021 | $49 |
| 2020 | $29 |
| 2019 | $22 |
| 2018 | $14 |
| 2017 | $10 |
|
Personalis Quarterly Research and Development Expenses (Millions of US $) |
|
|---|---|
| 2026-03-31 | $15 |
| 2025-12-31 | $13 |
| 2025-09-30 | $12 |
| 2025-06-30 | $12 |
| 2025-03-31 | $13 |
| 2024-12-31 | $11 |
| 2024-09-30 | $12 |
| 2024-06-30 | $13 |
| 2024-03-31 | $13 |
| 2023-12-31 | $14 |
| 2023-09-30 | $17 |
| 2023-06-30 | $18 |
| 2023-03-31 | $17 |
| 2022-12-31 | $17 |
| 2022-09-30 | $15 |
| 2022-06-30 | $16 |
| 2022-03-31 | $17 |
| 2021-12-31 | $15 |
| 2021-09-30 | $14 |
| 2021-06-30 | $12 |
| 2021-03-31 | $9 |
| 2020-12-31 | $9 |
| 2020-09-30 | $7 |
| 2020-06-30 | $6 |
| 2020-03-31 | $6 |
| 2019-12-31 | $7 |
| 2019-09-30 | $5 |
| 2019-06-30 | $4 |
| 2019-03-31 | $5 |
| 2018-12-31 | |
| 2018-09-30 | $4 |
| 2018-06-30 | $4 |
| 2017-12-31 | |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical - Generic Drugs | $0.630B | $0.070B |
| Personalis Inc. is a cancer genomics company. It is engaged in the development of therapies by providing molecular data about each patient's cancer and immune response. Personalis Inc. is based in Menlo Park, California. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Teva Pharmaceutical Industries (TEVA) | Israel | $35.437B | 10.97 |
| BridgeBio Pharma (BBIO) | United States | $14.460B | 0.00 |
| Dr Reddy's Laboratories (RDY) | India | $11.109B | 17.29 |
| Aspen Pharmacare (APNHY) | South Africa | $3.708B | 0.00 |
| Supernus Pharmaceuticals (SUPN) | United States | $2.918B | 22.33 |
| Bausch Health Cos (BHC) | Canada | $2.086B | 1.50 |
| Taysha Gene Therapies (TSHA) | United States | $1.290B | 0.00 |
| Amphastar Pharmaceuticals (AMPH) | United States | $0.924B | 7.28 |
| Assembly Biosciences (ASMB) | United States | $0.451B | 0.00 |
| Sol-Gel Technologies (SLGL) | Israel | $0.210B | 0.00 |
| Metagenomi Therapeutics (MGX) | United States | $0.052B | 0.00 |
| Evoke Pharma (EVOK) | United States | $0.019B | 0.00 |
| Teligent (TLGT) | United States | $0.000B | 0.00 |